Want to see HK:2496 full AI Analyst Report?
Wuhan YZY Biopharma Co., Ltd. Class H (2496) Ratios
Wuhan YZY Biopharma Co., Ltd. Class H Ratios
HK:2496's free cash flow for Q2 2026 was $-33.58M. For the 2026 fiscal year, HK:2496's free cash flow was decreased by $-5.36M and operating cash flow was $-28.21M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.66 | 1.19 | 1.44 | 1.63 | 2.21 |
| Quick Ratio | 0.64 | 1.17 | 1.41 | 1.55 | 2.05 |
| Cash Ratio | 0.50 | 0.68 | 1.13 | 0.92 | 1.19 |
| Solvency Ratio | -0.34 | -0.38 | -1.06 | -1.41 | -3.04 |
| Operating Cash Flow Ratio | -0.11 | -0.54 | -1.07 | -1.06 | -1.42 |
| Short-Term Operating Cash Flow Coverage | -0.22 | -1.33 | -2.08 | -2.03 | -2.88 |
| Net Current Asset Value | $ -96.18M | $ -15.97M | $ 76.13M | $ 109.91M | $ 79.13M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.73 | 0.48 | 0.30 | 0.25 | 0.17 |
| Debt-to-Equity Ratio | -2.41 | 4.17 | 0.71 | 0.43 | 0.20 |
| Debt-to-Capital Ratio | 1.71 | 0.81 | 0.41 | 0.30 | 0.17 |
| Long-Term Debt-to-Capital Ratio | -1.08 | 0.63 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -3.30 | 8.77 | 2.36 | 1.71 | 1.14 |
| Debt Service Coverage Ratio | -0.79 | -1.09 | -1.99 | -2.14 | -2.91 |
| Interest Coverage Ratio | -18.23 | -24.03 | 0.00 | -71.14 | -8.83 |
| Debt to Market Cap | 0.09 | 0.08 | 0.06 | 0.03 | 0.01 |
| Interest Debt Per Share | 0.68 | 0.68 | 0.49 | 0.36 | 0.23 |
| Net Debt to EBITDA | -0.33 | -0.01 | 0.67 | 0.40 | 0.31 |
| Profitability Margins | |||||
| Gross Profit Margin | 9.48% | 78.90% | 100.00% | 100.00% | 100.00% |
| EBIT Margin | -135.02% | -86.74% | -1382.12% | -7759.22% | -1085.82% |
| EBITDA Margin | -128.20% | -80.65% | -1328.53% | -7478.86% | -1028.11% |
| Operating Profit Margin | -135.02% | -90.90% | -1487.69% | -7759.22% | -1085.82% |
| Pretax Profit Margin | -126.73% | -90.53% | -1601.92% | -8346.50% | -1219.61% |
| Net Profit Margin | -126.73% | -90.53% | -1601.92% | -8346.50% | -1219.61% |
| Continuous Operations Profit Margin | -126.73% | -90.53% | -1768.96% | -8346.50% | -1219.61% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 93.87% | 99.59% | 107.68% | 107.57% | 112.32% |
| Return on Assets (ROA) | -47.14% | -36.44% | -63.32% | -71.02% | -90.93% |
| Return on Equity (ROE) | 155.58% | -319.63% | -149.61% | -121.16% | -103.74% |
| Return on Capital Employed (ROCE) | 344.30% | -119.94% | -138.78% | -147.59% | -124.25% |
| Return on Invested Capital (ROIC) | -117.22% | -62.07% | -81.45% | -78.12% | -83.72% |
| Return on Tangible Assets | -47.14% | -36.44% | -63.32% | -71.02% | -90.93% |
| Earnings Yield | -5.91% | -6.47% | -12.82% | -6.81% | -5.80% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.53 | 1.85 | 17.23 | 3.44 | 43.65 |
| Payables Turnover | 13.10 | 3.49 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 17.94 | 5.34 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 1.55 | 2.37 | 0.24 | 0.05 | 0.25 |
| Asset Turnover | 0.37 | 0.40 | 0.04 | 0.01 | 0.07 |
| Working Capital Turnover Ratio | -3.89 | 1.93 | 0.14 | 0.03 | 0.00 |
| Cash Conversion Cycle | 58.51 | 161.59 | 21.19 | 105.98 | 8.36 |
| Days of Sales Outstanding | 66.03 | 197.80 | 21.19 | 105.98 | 8.36 |
| Days of Inventory Outstanding | 20.35 | 68.37 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 27.87 | 104.57 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 86.37 | 266.16 | 21.19 | 105.98 | 8.36 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.11 | -0.52 | -1.00 | -0.80 | -0.42 |
| Free Cash Flow Per Share | -0.12 | -0.53 | -1.02 | -0.81 | -0.43 |
| Dividend Paid and CapEx Coverage Ratio | -24.27 | -66.88 | -96.38 | -125.23 | -51.87 |
| Capital Expenditure Coverage Ratio | -24.27 | -66.88 | -96.38 | -125.23 | -51.87 |
| Operating Cash Flow Coverage Ratio | -0.17 | -0.79 | -2.06 | -2.30 | -2.83 |
| Operating Cash Flow to Sales Ratio | -0.33 | -0.93 | -15.60 | -68.57 | -6.61 |
| Free Cash Flow Yield | -1.61% | -6.78% | -12.62% | -5.64% | -3.21% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -17.15 | -15.45 | -7.80 | -14.69 | -17.23 |
| Price-to-Sales (P/S) Ratio | 21.44 | 13.98 | 124.93 | 1226.10 | 210.13 |
| Price-to-Book (P/B) Ratio | -26.32 | 49.37 | 11.67 | 17.80 | 17.87 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -62.16 | -14.75 | -7.92 | -17.74 | -31.17 |
| Price-to-Operating Cash Flow Ratio | -64.72 | -14.97 | -8.01 | -17.88 | -31.77 |
| Price-to-Earnings Growth (PEG) Ratio | 1.07 | 0.28 | -0.48 | -0.54 | 0.00 |
| Enterprise Value Multiple | -17.06 | -17.35 | -8.73 | -16.00 | -20.12 |
| Enterprise Value | 1.42B | 1.51B | 1.38B | 2.71B | 2.52B |
| EV to EBITDA | -17.06 | -17.35 | -8.73 | -16.00 | -20.12 |
| EV to Sales | 21.87 | 13.99 | 115.99 | 1196.28 | 206.90 |
| EV to Free Cash Flow | -63.40 | -14.76 | -7.36 | -17.31 | -30.69 |
| EV to Operating Cash Flow | -66.01 | -14.98 | -7.43 | -17.45 | -31.28 |
| Tangible Book Value Per Share | -0.27 | 0.16 | 0.69 | 0.71 | 0.61 |
| Shareholders’ Equity Per Share | -0.27 | 0.16 | 0.69 | 0.81 | 0.74 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | -0.10 | 0.00 | 0.00 |
| Revenue Per Share | 0.34 | 0.56 | 0.06 | 0.01 | 0.06 |
| Net Income Per Share | -0.43 | -0.50 | -1.03 | -0.98 | -0.77 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.94 | 1.04 | 1.16 | 1.08 | 1.12 |
| Research & Development to Revenue | 1.12 | 1.53 | 12.96 | 69.53 | 9.27 |
| SG&A to Revenue | 0.32 | 0.14 | 1.86 | 3.95 | 0.59 |
| Stock-Based Compensation to Revenue | 0.02 | 0.00 | 0.00 | 0.61 | 2.66 |
| Income Quality | 0.25 | 1.03 | 1.07 | 0.94 | 0.66 |
Currency in CNY